Clinical Trials

1,902 enrolled

Breast Neoplasms

NCT06144944 2026-01-30

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

160 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT04290793 2026-01-07

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

113 enrolled

Breast Neoplasms

NCT04872985 2026-01-06

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

140 enrolled

Breast Neoplasms

NCT04193059 2025-11-26

PANSY

1,560 enrolled

Breast Neoplasms

NCT03515798 2025-09-12

PELICAN

52 enrolled

Inflammatory Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

325 enrolled

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00005584 2025-08-05

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

1,649 enrolled

Lymphoid

Hodgkin Disease, Lymphoma

NCT02455141 2025-07-11

TCTN

786 enrolled

Breast Neoplasms

NCT03725059 2025-07-11

KEYNOTE-756

1,240 enrolled

Breast Neoplasms

NCT04296175 2025-03-26

CITRINE

808 enrolled

Phase 2/3 Active not recruiting

Triple Negative Breast Neoplasms

NCT01924819 2025-03-04

TOPGEAR

574 enrolled

Gastrointestinal

Stomach Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT00798070 2024-12-18

PANTHER

2,017 enrolled

Breast Neoplasms, Neoplasms

NCT05165225 2024-11-29

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

48 enrolled

Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

70 enrolled

Triple Negative Breast Neoplasms

NCT00433420 2024-05-08

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

2,000 enrolled

Breast Neoplasms

NCT01996267 2024-03-29

TRAIN-2

437 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04172259 2023-10-16

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

156 enrolled

Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

62 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00496795 2022-06-29

DDP

100 enrolled